Paper Details

  1. Home
  2. Paper Details

Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.

Author: AndersonIan, BurnsAlison, CampbellJohn, Chew-GrahamCarolyn, DaviesSimon, DickensChris, GilbodySimon, HollingworthWilliam, KesslerDavid, LewisGlyn, MacNeillStephanie, MacleodUna, PetersTim J, RoundJeff, TallonDebbie, WilesNicola

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Mirtazapine, in addition to a serotonin-noradrenaline reuptake inhibitor (SNRI) or selective serotonin reuptake inhibitor (SSRI) antidepressant, did not provide a clinically important benefit over placebo in primary care patients with treatment-resistant depression (TRD). There was no evidence that the addition of mirtazapine was cost-effective.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Depression is usually managed in primary care and antidepressants are often the first-line treatment, but only half of those treated respond to a single antidepressant. OBJECTIVES: To investigate whether or not combining mirtazapine with serotonin-noradrenaline reuptake inhibitor (SNRI)...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287172/

データ提供：米国国立医学図書館（NLM）

Mirtazapine for Treatment-Resistant Depression: A Search for a New Oasis

Treatment-resistant depression (TRD) is a challenging condition that affects a significant portion of individuals with depression. This study investigates the effectiveness of adding mirtazapine to existing SSRI or SNRI antidepressant treatment in patients with TRD. The researchers conducted a large-scale, randomized controlled trial involving 480 patients who were already taking an SSRI or SNRI antidepressant. Participants were randomly assigned to receive either mirtazapine or a placebo in addition to their usual antidepressant. The primary outcome measure was depression severity, assessed using the Beck Depression Inventory-II (BDI-II). The results showed no significant difference in depression severity between the mirtazapine and placebo groups at 12 weeks.

Mirtazapine: A Potential, but Unproven, Solution for TRD

This study provides evidence that adding mirtazapine to existing SSRI or SNRI treatment does not significantly improve depression severity in patients with TRD. This finding suggests that mirtazapine may not be a consistently effective treatment option for TRD in primary care settings.

The Desert of Depression: A Complex Landscape of Challenges

Finding effective treatments for TRD is a challenging but essential goal in mental health care. This study underscores the complexity of depression and the need for ongoing research to identify new treatment options that can effectively address this challenging condition.

Dr.Camel's Conclusion

This study did not find convincing evidence that mirtazapine, when added to existing SSRI or SNRI treatment, offers significant benefits for patients with TRD. The search for effective treatments for this challenging condition continues.

Date :
  1. Date Completed 2019-04-09
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

30468145

DOI: Digital Object Identifier

PMC6287172

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.